Phibro Animal Health Corp

Phibro Animal Health Corp(PAHC)股票分析

$38.800

-0.986 (-2.54%)收盤時

Loading chart…
最高
39.510
開盤
39.510
成交量加權均價
38.98
成交量
102.86K
市值
696.66M
最低
38.620
成交金額
4.01M
企業價值/稅息折舊攤銷前利潤(TTM)
10.41

Phibro Animal Health Corporation is a diversified developer, manufacturer and marketer of a range of animal health and mineral nutrition products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture and dogs. The Company is also a manufacturer and marketer of performance products for use in the personal care, industrial chemical and chemical catalyst industries. Its segments include Animal Health, Mineral Nutrition and Performance Products. The Animal Health segment develops, manufactures and markets antibacterials which inhibit the growth of pathogenic bacteria that cause infections in animals. The Mineral Nutrition segment manufactures and markets formulations and concentrations of trace minerals such as zinc, manganese, copper, iron and other compounds. The Performance Products segment manufactures and markets specialty ingredients for use in the personal care, industrial chemical and chemical catalyst industries.

AI 分析 of Phibro Animal Health Corp (PAHC)

買進

Phibro Animal Health Corp is a good buy right now due to its strong recent financial performance, with a 37% increase in adjusted net income for Q4 2026 reaching $35 million, and a projected earnings per share for 2027 between $2.98 and $3.22, indicating continued profitability growth. The current price of $38.82 is below the analyst price target of $44, suggesting a potential upside of approximately 13.5%. However, the main risk is the debt to equity ratio, which stands at 190.10%, indicating a high level of leverage that could impact financial stability if not managed carefully.

分析師評級(6)

上檔空間 +22.42%
賣出
1 買進
2 持有
3 賣出
目前: 38.80
最低
45.00
平均
47.50
最高
50.00

Citi

2026-05-14

目標價

$44

中性

Citi

2026-05-13

目標價

$44

中性

Citi

2026-04-15

目標價

$62

中性

Morgan Stanley

2026-02-06

目標價

$49

Equal Weight

JPMorgan

2025-11-07

目標價

$50

增持

估值指標

Phibro Animal Health Corp(PAHC)目前預期本益比為 13.83,5 年平均預期本益比為 12.60。

預期本益比

合理
5 年均值 P/E
12.60
目前P/E
13.83
高估
14.86
低估
10.35

預期 EV/EBITDA

高估
5 年均值 EV/EBITDA
8.80
目前EV/EBITDA
10.41
高估
10.04
低估
7.56

預期股價營收比

合理
5 年均值 P/S
0.76
目前P/S
0.99
高估
1.00
低估
0.53

持有 PAHC 的大戶

C

Castleknight Management LP

+ 持有PAHC

-1.82%

3個月報酬率

事件時間軸

2026-08-26 (ET)

20:00:00

Salesforce Shares Rise 12.8% After Earnings Boost

16:30:00

Phibro Animal Health Q4 Revenue $396.7M Beats Expectations

16:30:00

Sees FY27 Revenue of $1.55B to $1.6B

2026-05-06 (ET)

16:50:00

Raises FY26 Revenue Outlook to $1.46B-$1.5B

16:40:00

Phibro Animal Health Reports Q3 Revenue of $383.5M

資訊

PAHC 常見問題 —— 由 Alphio AI 解答

Phibro Animal Health Corporation is a diversified developer, manufacturer and marketer of a range of animal health and mineral nutrition products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture and dogs. The Company is also a manufacturer and marketer of performance products for use in the personal care, industrial chemical and chemical catalyst industries. Its segments include Animal Health, Mineral Nutrition and Performance Products. The Animal Health segment develops, manufactures and markets antibacterials which inhibit the growth of pathogenic bacteria that cause infections in animals. The Mineral Nutrition segment manufactures and markets formulations and concentrations of trace minerals such as zinc, manganese, copper, iron and other compounds. The Performance Products segment manufactures and markets specialty ingredients for use in the personal care, industrial chemical and chemical catalyst industries. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Phibro Animal Health Corp is a good buy right now due to its strong recent financial performance, with a 37% increase in adjusted net income for Q4 2026 reaching $35 million, and a projected earnings per share for 2027 between $2.98 and $3.22, indicating continued profitability growth. The current price of $38.82 is below the analyst price target of $44, suggesting a potential upside of approximately 13.5%. However, the main risk is the debt to equity ratio, which stands at 190.10%, indicating a high level of leverage that could impact financial stability if not managed carefully.

6 analysts cover PAHC: 1 rate it Buy, 2 Hold and 3 Sell. The average price target is 47.50.

暫無貼文

註冊或登入後參與討論

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易